Icosavax Revenue
Biotechnology Research • 
Seattle, Washington, United States • 21-50 Employees
Icosavax revenue & valuation
| Annual revenue | $582,000 |
| Revenue per employee | $21,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $1,900,000 |
| Total funding | $67,800,000 |
Key Contacts at Icosavax
Kevin Degiusti
Director Of Drug Substance Operations
Geremy Knapp
Director Of Quality Control
Ross Taylor
Director, Translational Cmc
Company overview
| Headquarters | 1930 Boren Ave, Suite 1000, Seattle, Washington 98101, US |
| Phone number | +12063365600 |
| Websites | |
| NAICS | 541714 |
| Keywords | Infectious Disease, Vaccines, Vaccine, Vaccine Development, RSV, Respiratory Syncytial Virus, Vlps |
| Founded | 2018 |
| Employees | 21-50 |
| Socials |
Icosavax Email Formats
Icosavax uses 1 email format. The most common is {first name}.{last name} (e.g., john.doe@astrazeneca.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@astrazeneca.com | 100% |
About Icosavax
Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. The company was founded on breakthrough computationally-designed virus like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington. Icosavax is located in Seattle. Icosavax is a member of the AstraZeneca Group.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Icosavax has 5 employees across 3 departments.
Departments
Number of employees
Lithuania
Canada
Guatemala
SpainFrequently asked questions
4.8
40,000 users
